What is the 13F Pro Quality Score for NEPH?

13F Pro ranks NEPHROS INC (NEPH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NEPH's current score at https://13fpro.ai/company/NEPH (free sign-up required for the full ranking).

Where does 13F Pro source NEPH data?

All NEPHROS INC fundamentals and ownership data come directly from SEC EDGAR. NEPHROS INC files with the SEC under CIK 1196298. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NEPH in?

NEPHROS INC (NEPH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NEPH research updated on 13F Pro?

NEPH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

NEPHROS INC(NEPH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1196298 NEPH stock profile & AI dashboard →

13F Pro Quality Score

50.4/100

Rank #1,602 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why NEPH Scores 50/100

exact factor attribution · 2026-09-11

NEPH's composite is driven by revenue growth and capital efficiency, held back by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+6.0 pts

80th pct

Capital efficiency

+4.0 pts

90th pct

Profitability

+1.9 pts

63th pct

Shareholder dilution

-0.1 pts

48th pct

Earnings quality

-0.3 pts

48th pct

Earnings growth

-0.3 pts

45th pct

Institutional flow

-1.7 pts

16th pct

Free cash flow

-3.3 pts

28th pct

Scale

-5.9 pts

11th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

NEPH Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for NEPHROS INC (NEPH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NEPH at 50.4/100 on a 32-signal composite quality model, placing it at rank #1,602 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), NEPHROS INC reports quarterly revenue of $6.0M, net income of $1.2M. Top institutional holders of NEPH by reported 13-F value include WEXFORD CAPITAL, Topline Capital Management, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. NEPH trades on the Nasdaq exchange and files with the SEC under CIK 1196298. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NEPH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NEPHROS INC directly from SEC EDGAR. NEPHROS INC's 13F Pro composite quality score has ranged between 50 and 54 since 2026, currently 50.4 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.

✦

Fun facts about NEPHROS INC

Quirks, history, and lore behind NEPH — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap healthcare company listed on Nasdaq, headquartered in New Jersey, focused on water purification for medical applications.
2
The Numbers
Annual revenues in the low tens of millions of dollars — this is a micro-cap operation, not a giant, but it serves a very specialized and critical niche.
3
The History
Founded in the late 1990s, the company grew out of research into ultrafiltration membrane technology and has spent decades targeting the dialysis and hospital water markets.
4
The Secret
Its core technology uses hollow-fiber ultrafilters to remove bacteria and endotoxins from water — the kind of purity that keeps dialysis patients from being poisoned by their own treatment.
5
The Lore
The company also sells water quality monitoring products and has pushed into the military and emergency water purification market, making clean water anywhere a mission.
6
The Giveaway
Its ticker is practically a kidney joke — this maker of dialysis-grade water filters trades under a symbol that rhymes with the organ its patients rely on.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$6.0M

Net Income

Q2 2026

$1.2M

ROIC

Q2 2026

40.5%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+32.7% YoY

$18.8MFY 2025

FY22 $10.0MFY23 $14.2MFY24 $14.2MFY25 $18.8M

Net Income

+1513.5% YoY

$1.2MFY 2025

FY22 —FY23 $-1.6MFY24 $74.0KFY25 $1.2M

Operating Income

+19000.0% YoY

$1.1MFY 2025

FY22 $-4.3MFY23 $-1.6MFY24 $6.0KFY25 $1.1M

EPS (Diluted)

+1000.0% YoY

$0.11FY 2025

FY22 $-0.73FY23 $-0.15FY24 $0.01FY25 $0.11

Total Assets

+21.7% YoY

$13.6MFY 2025

FY22 $11.0MFY23 $11.9MFY24 $11.2MFY25 $13.6M

Total Debt

—FY 2025

FY22 $71.0KFY23 —FY24 —FY25 —

Op. Cash Flow

+434.3% YoY

$1.6MFY 2025

FY22 $-3.2MFY23 $827.0KFY24 $-492.0KFY25 $1.6M

Free Cash Flow

—FY 2025

FY22 $-3.4MFY23 $752.0KFY24 $-547.0KFY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$18.8M +32.7%	$14.2M -0.5%	$14.2M +42.7%	$10.0M -2.4%	$10.2M +19.3%	$8.6M
Net Income	$1.2M +1513.5%	$74.0K +104.7%	$-1.6M	—	$-3.9M +14.6%	$-4.5M
Operating Income	$1.1M +19000.0%	$6.0K +100.4%	$-1.6M +63.3%	$-4.3M -33.3%	$-3.3M +23.9%	$-4.3M
EPS (Diluted)	$0.11 +1000.0%	$0.01 +106.7%	$-0.15 +79.5%	$-0.73	—	—
Total Assets	$13.6M +21.7%	$11.2M -5.5%	$11.9M +7.8%	$11.0M -37.7%	$17.6M -4.6%	$18.5M
Total Debt	—	—	—	$71.0K -79.3%	$343.0K -42.2%	$593.0K
Operating Cash Flow	$1.6M +434.3%	$-492.0K -159.5%	$827.0K +125.6%	$-3.2M -128.2%	$-1.4M +79.5%	$-6.9M
Free Cash Flow	—	$-547.0K -172.7%	$752.0K +122.3%	$-3.4M -132.0%	$-1.5M +79.7%	$-7.1M

Get alerted when NEPH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for NEPHROS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NEPH

WEXFORD CAPITAL LP
$12.9M3,600,552 sh
Topline Capital Management, LLC
$1.9M535,698 sh
VANGUARD CAPITAL MANAGEMENT LLC
$709.2K198,643 sh
MORGAN STANLEY
$460.2K128,915 sh
Cornerstone Capital, Inc.
$459.5K128,700 sh
BARD ASSOCIATES INC
$421.3K118,003 sh
RENAISSANCE TECHNOLOGIES LLC
$276.7K77,504 sh
GEODE CAPITAL MANAGEMENT, LLC
$250.9K70,263 sh
Mesirow Financial Investment Management, Inc.
$214.2K60,000 sh
HighTower Advisors, LLC
$213.2K59,710 sh

Fund	Value	Shares
WEXFORD CAPITAL LP	$12.9M	3,600,552
Topline Capital Management, LLC	$1.9M	535,698
VANGUARD CAPITAL MANAGEMENT LLC	$709.2K	198,643
MORGAN STANLEY	$460.2K	128,915
Cornerstone Capital, Inc.	$459.5K	128,700
BARD ASSOCIATES INC	$421.3K	118,003
RENAISSANCE TECHNOLOGIES LLC	$276.7K	77,504
GEODE CAPITAL MANAGEMENT, LLC	$250.9K	70,263
Mesirow Financial Investment Management, Inc.	$214.2K	60,000
HighTower Advisors, LLC	$213.2K	59,710

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NEPH on your watchlist

Track score changes the day NEPHROS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NEPH a good stock to buy?

13F Pro's AI-powered analysis of NEPHROS INC (NEPH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NEPH are available on the NEPH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NEPH is classified as a small company.

Which hedge funds own NEPH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NEPH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NEPHROS INC's investment landscape.